EUCTR2004-001894-24-DK进行中（未招募）不适用
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine combination or Paroxetine monotherapy to Placebo in Patients with Social Anxiety Disorder (SAD)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 204
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject has a primary diagnosis of Generalised Social Anxiety Disorder/Social Phobia as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, (DSM-IV, 300.23) diagnosed using psychiatric confirmation of diagnosis in conjunction with the Mini International Neuropsychiatric Interview (MINI), Clinician Rated version 5.0.
- •Note: a diagnosis of Generalised Social Anxiety Disorder will be considered to have been established if the subject reports/admits to four or more phobic situations including at least two which are interactional situations.
- •2. Male and female subjects must be 18-65 years of age.
- •3. Subjects must be willing to restrict alcohol intake to 3 units or less per day for males, 2 units or less per day for females. A unit is equivalent to 300 mL of beer or one measure of spirits or one glass of wine.
- •4. The subject must have the ability to comprehend the key components of the consent form and must have given written informed consent to participate in the study prior to commencing any study specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects who score 1 or 2 on the CGI global improvement item at baseline.
- •2. Subjects with a score 15 or more on the HAMD17item at screening.
- •3. Subjects who meet DSM-IV criteria for any other Axis I disorder as a primary diagnosis at or within 6 months prior to the screening visit.
- •4. Subjects with body dysmorphic disorder.
- •5. Subjects with a history of schizophrenia, schizoaffective disorder, or a bipolar disorder.
- •6. Subjects who meet DSM-IV criteria for substance abuse (alcohol or drugs) currently or within 6 months prior to screening
- •7. Subjects who meet DSM-IV criteria for substance dependence (other than nicotine or caffeine) currently or within 6 months prior to screening.
- •8. Subjects have any screening laboratory value outside of the Sponsor-specified ranges at the Screening Visit. Testing may be repeated once to see if the value returns to within range but any such laboratory abnormality must be resolved by the Baseline Visit.
- •9. Subjects have any laboratory abnormality that in the Investigator’s judgement is considered to be clinically significant and not resolved by the Baseline Visit (even if not outside of Sponsor-specified ranges).
- •10. Subjects have a positive urine test at Screening for illicit drug use and/or a history of substance abuse or dependence (alcohol or drugs) within the past 12 months. Subjects have a blood alcohol level of =15 mg/dL (0.015%) at the Screening Visit.
- •11. Subjects with an unstable medical disorder; or a disorder that would likely interfere with the action, absorption, distribution, metabolism or excretion of GW597599 or paroxetine; may pose a safety concern; or interfere with the accurate assessment of safety or efficacy.
- •12. Subjects with a history of myocardial infarction within one year prior to the Screening Visit.
- •13. Subjects who are not euthyroid based on lab results at the Screening Visit. Subjects maintained in thyroid medication must be euthyroid for a period of at least six months prior to the Screening Visit.
- •14. Subjects have any screening electrocardiographic (ECG) parameter outside of the Sponsor-specified ranges; the ECG may be repeated once to see if the parameter returns to within range but any such abnormality must be resolved by the Baseline Visit.
- •15. Subjects have any ECG finding that in the Investigator’s judgement is considered to be clinically significant and not resolved by the Baseline Visit.
- •16. Subjects who have taken any of the following psychotropic drugs or antidepressants (including monoamine oxidase inhibitors, MAOI's) must have stopped taking these drugs within the time frames specified below prior to the Baseline Visit (for a listing see the protocol). All of the above psychotropic drugs are not allowed for the duration of the study, including the two-week period preceding the mandatory 14-Day Follow-up Visit. All other (non-psychotropic) drugs metabolised via the P450 3A4 pathway must be discontinued from screening and are not allowed for the duration of the study.
- •17. Subjects who are currently participating in another clinical trial in which the subject is or will be exposed to an investigational or non-investigational drug or device, or has done so within the preceding month for studies unrelated to SAD, or 12 months for studies related to SAD.
- •18. Subjects who have received electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) within the 6 months prior to the Screening Visit.
- •19. Subjects receiving or planning to undergo regular
研究者
相似试验
尚未招募
2 期
A Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson’s DiseaseParkinson’s DiseaseNeurological - Parkinson's diseaseACTRN12623000843651niversity of Sydney240
尚未招募
2 期
Study of PAX-1 in Patients With Persistent Cancer Pain in the Palliative SettingACTRN12615000987561Bio And Gene Pty Ltd120
进行中（未招募）
不适用
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine combination or Paroxetine monotherapy to Placebo in Patients with Social Anxiety Disorder (SAD)Subjects with Social Anxiety Disorder (SAD)EUCTR2004-001894-24-DEGlaxoSmithKline Research & Development Limited204
招募中
2 期
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Three Re-Purposed Medications in Moderate Severity Parkinson’s DiseaseParkinson’s DiseaseNeurological - Parkinson's diseaseACTRN12620000560998niversity of Sydney240
进行中（未招募）
1 期
A Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteriod Use in Adults with Oral Corticosteriod Dependent AsthmaSevere AsthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2021-006691-17-CZAstraZeneca AB207